ALTIMMUNE INC. DL-,0001 WKN: A2N5Z6 ISIN: US02155H2004 Kürzel: ALT Forum: Aktien Thema: Hauptdiskussion

1. Altimmune's MOMENTUM trial: 74.5% weight loss from fat, mirroring diet/exercise effects. 2. IMPACT Phase 2b MASH trial with pemvidutide ongoing; results expected Q1 2025. 3. Pemvidutide shows anti-fibrotic effects in liver fibrosis preclinical models. 4. 2023 end-of-year cash: $198 million. 5. Pemvidutide led to 15.6% weight loss over 48 weeks, significant lipid and liver fat reduction in Phase 2 obesity trial. 6. FDA Fast Track designation for pemvidutide in MASH, with IMPACT trial focused on MASH resolution. 7. Pemvidutide may also reduce cardiovascular risk, shown in cholesterol transport studies. 8. HepTcell development halted post Phase 2 hepatitis B trial. 9. Q4 financials: R&D $16.9M, G&A $4.3M, net loss $31.6M. 10. Pemvidutide's efficacy in obesity and MASH backed by trials, indicating strong therapeutic potential. Bisher großartige Ergebnisse, es geht aktuell um Studien und die finanzergebnisse, noch nichts darüber wie es weitergehen könnte...falls etwas kommt.

Kerrisdale Capital hatte scheinbar doch recht